BioSpace News Archive

Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today it plans to host a virtual information session on its pipeline product, HT-005 Z-Pods™ , a novel endocannibinoid treatment for patients with Cutaneous Lupus Erythematosus (CLE), on Tuesday, May 18th at 11:00am ET

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, today announced that Nai-Kong V. Cheung, MD, PhD, Enid A. Haupt Endowed Chair, Pediatric Oncology, Memorial Sloan Kettering Cancer Center (“MSK”) will present a research update on the Company’s SADA technology platform at PEGS Boston Virtual Conference

Omeros Corporation (Nasdaq: OMER) today announced that data on organ function improvement from Omeros’ pivotal trial of narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) will be shared as an oral presentation at the 2021 European Hematology Association (EHA) Virtual Congress.

New product and software update for existing devices available May 12, 2021

MannKind Corporation is revved up to announce an elevated partnership for the 2021 season with NTT INDYCAR SERIES driver Conor Daly, who is living with Type 1 diabetes and will help raise awareness about diabetes and innovative management options.

Genetic Technologies Limited, a diversified Genomics and AI driven preventative health business, announced an interview with Simon Morriss, CEO, will air on The RedChip Money Report® on the Bloomberg Network in the U.S. on Saturday, May 15th, at 7 p.m. local time in 73M homes across the United States.

Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today provided a corporate update and reported financial results for the first quarter ended March 31, 2021.

Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, reported financial results for the first quarter ended March 31, 2021 and provided an update on business progress.

Biogen Inc. (Nasdaq: BIIB) and Envisagenics today announced a new collaboration to advance ribonucleic acid (RNA) splicing research within central nervous system (CNS) diseases.

Ovid Therapeutics Inc. (NASDAQ: OVID) (“Ovid”), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today reported financial results for the quarter ended March 31, 2021 and provided an overview of the Company’s recent progress.